Skip to content
‹ Back to IndustriesSciences

LISTEN: Astronomers just spotted a new ‘Super Earth’ planet that feels a whole lot like home

Astronomers have identified K2-18b as a Super Earth, initially discovered in 2015, which shows promising resemblances to Earth. The planet's composition is uncertain, possibly either rocky with a gaseous atmosphere or a water world with an icy surface. Upcoming observations with the James Webb Space Telescope aim to uncover the atmospheric nature of K2-18b.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · ·
Share

Key takeaways

01

K2-18b is categorized as a Super Earth, discovered in 2015.

02

The planet's composition might be rocky with a gaseous atmosphere or a water planet with ice.

03

The James Webb Space Telescope will help determine the atmospheric details of K2-18b.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Astronomers have discovered a new SUPER EARTH planet that could be the next frontier. K2-18b was originally discovered in 2015 but after further study by astronomers has been categorized as a SUPER EARTH planet. Right now, scientists have narrowed down the planets makeup to being either mostly rocky with a gaseous atmosphere like Earth OR a water planet with thick layers of ice covering its surface. “With the current data, we can’t distinguish between those two possibilities,” says Ryan Cloutie, PhD student at University of Toronto Scarborough. “But with NASA’s James Webb Space Telescope we can probe the atmosphere and see whether it has an extensive atmosphere or it’s a planet covered in water.” It’s sounds like the next Earth is in a galaxy not so far away after all.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

SR-Tiget gene therapy families average six months in Milan and years of lab tests

SR-Tiget gene therapy families average six months in Milan and years of lab tests

Gene therapy at Milan’s SR-Tiget includes a family support programme that helps relatives manage months-long stays (often around six months) for treatment, while a regulated lab can track patient samples for up to 20 years. Follow-up visits can outnumber new treatments, adding to the long-term workload.

  • 01In 2025, SR-Tiget's family programme coordinated 133 follow-up visits against 17 new treatments. That gap keeps widening because each patient enters roughly 15 years of twice-yearly checkups.
  • 02At SR-Tiget, the average family spends six months in Milan, and the child's samples can keep reaching the lab for as long as twenty years.
  • 03Any gene therapy service has to answer one question: who tells the lab when a child's fever pushes a blood draw from morning to afternoon? In Milan, research nurses own that handoff.

Nov 16, 2026

Two photonic AI components reach outside testers—on limits

Two photonic AI components reach outside testers—on limits

Kopin is expanding microLED manufacturing in Westborough, Massachusetts, which could add up to 80 jobs over five years. Its microLEDs will go to military displays and to Neural I/o, an interconnect that sends AI data as light. In the same news round-up, Q.ANT and IONOS opened a photonic processor pilot where approved applicants can run their own workloads.

  • 01Two photonic approaches tied to AI’s power problem reached testable hardware this month: PsiQuantum’s 8×8 optical switch samples and Q.ANT’s second-generation processor via an IONOS bare-metal pilot in Germany.
  • 02PsiQuantum is sending samples of an 8×8 demonstration optical circuit switch to selected prospective customers, giving buyers hardware they can test even though commercial products and full specs are still pending.
  • 03Staffing may not keep up with demand: a 2023 Applied Optics study projected US demand for 42,000 new middle-skilled photonics workers by 2030, and expansions like Kopin's could draw from that same pool.

Nov 15, 2026

Lilly breaks ground on a $5B Virginia bioconjugate plant; first building expected in 2030

Lilly breaks ground on a $5B Virginia bioconjugate plant; first building expected in 2030

Lilly’s Goochland County site is designed to make APIs and finished medicines on one campus. Virginia Business reported the first building is expected to open in 2030.

  • 01Goochland’s pilot-scale training center is slated to open in 2028, two years before Lilly expects its first production building in 2030—signaling workforce readiness as the earliest milestone at Lilly’s first dedicated, fully integrated API and drug product facility for its bioconjugate platform and monoclonal antibody portfolio.
  • 02For anyone tracking new ADC supply, Goochland is a later story: Lilly expects to open the first building in 2030 and the second in 2031.

Nov 15, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

S
Sciences
RC
Ryan Cloutie

PhD student

University of Toronto Scarborough

Ryan Cloutie is a PhD student at the University of Toronto Scarborough. He is involved in research to determine the atmospheric composition of exoplanets using advanced telescopes. His work contributes to the understanding of exoplanetary atmospheres and their potential similarities to Earth's.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512